KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortes,David W. Cescon,Hope S. Rugo,Zbigniew Nowecki,Seock-Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos Henrique Barrios,Esther Holgado,Hiroji Iwata,Norikazu Masuda, Marco Torregroza Otero,Erhan Gokmen,Sherene Loi,Zifang Guo,Jing Zhao,Gursel Aktan,Vassiliki Karantza,Peter Schmid

Journal of Clinical Oncology（2020）

引用 124|浏览46

暂无评分

摘要

1000Background: Pembrolizumab (pembro) monotherapy showed promising antitumor activity and manageable safety in patients (pts) with metastatic TNBC in KEYNOTE-012, -086 and -119. KEYNOTE-355 (Clini...

查看译文

关键词

pembrolizumab,breast cancer,chemotherapy,double-blind,triple-negative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要